SK BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83,500 KRW | +0.24% |
|
+0.97% | -16.83% |
| Jan. 30 | SK Biopharmaceuticals Swings to Profit in Q4 | MT |
| 2023 | SK Group Advances Net Zero Transition via Key Renewable Energy Deal | MT |
| Sales 2024 * | 485B 353M | Sales 2025 * | 651B 473M | Capitalization | 6,539B 4.75B |
|---|---|---|---|---|---|
| Net income 2024 * | 31B 22.54M | Net income 2025 * | 118B 85.79M | EV / Sales 2024 * | 13.2 x |
| Net cash position 2024 * | 145B 105M | Net cash position 2025 * | 261B 190M | EV / Sales 2025 * | 9.65 x |
| P/E ratio 2024 * |
205
x | P/E ratio 2025 * |
50
x | Employees | 252 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 35.75% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.24% | ||
| 1 week | +0.97% | ||
| Current month | -8.94% | ||
| 1 month | -11.17% | ||
| 3 months | -5.11% | ||
| 6 months | +10.74% | ||
| Current year | -16.83% |
1 week
82 600.00
86 100.00
1 month
80 700.0094 800.00
Current year
80 700.00104 800.00
1 year
67 200.00104 800.00
3 years
50 900.00137 500.00
5 years
50 900.00269 500.00
10 years
50 900.00269 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dong-Hoon Lee
CEO | Chief Executive Officer | 56 | 22-12-31 |
Choi Jonggil
PRN | Corporate Officer/Principal | - | 22-12-31 |
Jeong-Woo Jo
PRN | Corporate Officer/Principal | - | 17-03-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Geun-Joo Hwang
BRD | Director/Board Member | 60 | 17-03-15 |
Jeong-Woo Jo
PRN | Corporate Officer/Principal | - | 17-03-15 |
Young-Ju Bang
BRD | Director/Board Member | - | 19-08-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.83% | 2 M€ | -14.14% | ||
| 0.08% | 15 M€ | +11.24% | ||
| 0.03% | 2,808 M€ | +5.90% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 83,500 | +0.24% | 37,526 |
| 24-04-25 | 83,300 | -2.00% | 80,223 |
| 24-04-24 | 85,000 | +1.19% | 58,324 |
| 24-04-23 | 84,000 | -0.24% | 65,826 |
| 24-04-22 | 84,200 | +1.81% | 70,684 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
83,500
KRW
Average target price
106,133
KRW
Spread / Average Target
+27.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.83% | 4.75B | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- A326030 Stock
